ACCOUNT

Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

PGe
NEWSLETTERS
PG STORE
ARCHIVES

CLASSIFIEDS

OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS

CONTACT US
ADVERTISING
CAREER OPPORTUNITIES

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Mersana Therapeutics, Inc. - Common Stock (NQ:MRSN)

29.08 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mersana Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Looking Into Mersana Therapeutics's Return On Capital Employed ↗

March 01, 2022

Mersana Therapeutics (NASDAQ:MRSN) brought in sales totaling $11.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 7.72%, resulting in...

Via Benzinga

Recap: Mersana Therapeutics Q4 Earnings ↗

February 28, 2022

Mersana Therapeutics (NASDAQ:MRSN) reported its Q4 earnings results on Monday, February 28, 2022 at 06:00 AM. Here's what investors need to know about the announcement...

Via Benzinga

Earnings Scheduled For February 28, 2022 ↗

February 28, 2022

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...

Via Benzinga

78 Biggest Movers From Friday ↗

February 14, 2022

Gainers Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) surged 26% to close at $2.24. Y-mAbs reported completion of pre-BLA meeting with the FDA for Omburtamab. China Online Education...

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

February 18, 2022

On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

February 16, 2022

On Wednesday, 115 companies reached new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

February 11, 2022

Gainers Avenue Therapeutics (NASDAQ:ATXI...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

February 10, 2022

Gainers Avenue Therapeutics (NASDAQ:ATXI)...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

February 09, 2022

Gainers Doximity (NYSE:DOCS) shares increased by 23.7% to $61.61 during Wednesday's regular session. Doximity's stock is trading at a volume of 8.5 million shares...

Via Benzinga

40 Stocks Moving In Wednesday's Mid-Day Session ↗

February 09, 2022

Gainers US Ecology, Inc. (NASDAQ: ECOL) shares jumped 68.1% to $47.34 after Republic Services reported it will buy the company at $48 per share in cash. Tritium DCFC Limited (...

Via Benzinga

60 Biggest Movers From Yesterday ↗

February 10, 2022

Gainers US Ecology, Inc. (NASDAQ: ECOL) shares surged 67.7% to close at $47.25 on Wednesday after Republic Services reported it will buy the company at $48 per share in cash....

Via Benzinga

The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In ↗

February 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Janssen Inks Over $1B Pact For Mersana's ADC Technology In Three targets ↗

February 03, 2022

Mersana Therapeutics Inc (NASDAQ: MRSN) has announced a

Via Benzinga

The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation ↗

February 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

February 03, 2022

Gainers SOC Telemed (NASDAQ:TLMD) shares increased by 338.2% to $2.82 during Thursday's pre-market session. The market value of their outstanding shares is at $284.5...

Via Benzinga

Sutro Biopharma Collapses; Why One Analyst Remains Bullish On Its Chances In Cancer ↗

January 06, 2022

Sutro Biopharma could still find a place for itself in ovarian cancer treatment.

Via Investor's Business Daily

The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets ↗

January 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,...

Via Benzinga

Mersana Therapeutics, Synaffix Expand Cancer Pact To Potential Value Exceeding $1B ↗

November 30, 2021

Synaffix B.V. has expanded its license agreement with Mersana Therapeutics Inc (NASDAQ: MRSN) for antibody-drug conjugates (ADCs) targeting cancers. The...

Via Benzinga

Mersana Therapeutics's Return On Capital Employed Insights ↗

November 10, 2021

Mersana Therapeutics (NASDAQ:MRSN) brought in sales totaling $11.00 thousand during Q3 according to data provided by Benzinga Pro. However, earnings decreased 11.17%, resulting in...

Via Benzinga

Mersana Highlights New Preclinical Data For XMT-2056 Cancer Settings ↗

October 08, 2021

Mersana Therapeutics Inc (NASDAQ: MRSN) has announced new preclinical data of XMT-2056. Data were presented at the AACR-NCI-EORTC Virtual International Conference...

Via Benzinga

45 Stocks Moving In Monday's Mid-Day Session ↗

September 13, 2021

Gainers Aterian, Inc. (NASDAQ: ATER) jumped 54.1% to $18.18. Investor presentation released on Friday is now circulating on news outlets. Itamar Medical Ltd. (NASDAQ: ITMR)...

Via Benzinga

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗

November 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

September 10, 2021

Gainers IVERIC bio (NASDAQ:ISEE) shares increased by 63.11% to $14.18 during Friday's regular session. IVERIC bio's stock is trading at a volume of 120.3 million...

Via Benzinga

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs ↗

October 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...

Via Benzinga

72 Biggest Movers From Yesterday ↗

September 14, 2021

Gainers aTyr Pharma, Inc. (NASDAQ: LIFE) jumped 67% to settle at $9.15 on Monday as the company announced positive results from its Phase 1b/2a trial evaluating its lead...

Via Benzinga

41 Stocks Moving In Friday's Mid-Day Session ↗

September 10, 2021

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares climbed 64.4% to $14.29 after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in geographic...

Via Benzinga

60 Biggest Movers From Friday ↗

September 13, 2021

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares surged 62.5% to close at $14.12 on Friday after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in...

Via Benzinga

Why Are Mersana Therapeutics Shares Trading Lower On Friday? ↗

September 10, 2021

Mersana Therapeutics Inc (NASDAQ: MRSN) stock is moving lower during the market trading session. Investors are reacting to interim data from the ovarian cancer Phase 1 trial...

Via Benzinga

Mid-Morning Market Update: Markets Mixed; Kroger Tops Q2 Views ↗

September 10, 2021

Following the market opening Friday, the Dow traded down 0.15% to 34,827.04 while the NASDAQ rose 0.32% to 15,296.61. The S&P also rose, gaining 0.03% to 4,494.53. The U.S....

Via Benzinga

Topics Stocks

The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test ↗

September 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.